BioVie Finishes Dosing in Long COVID Brain Fog Study, Data Due in September
BioVie has wrapped up the treatment portion of its ADDRESS-LC trial testing bezisterim against long COVID-related cognitive and fatigue symptoms. The study, backed by the U.S. Department of War, involved roughly 200 participants. Topline findings are slated for release before the end of September 2026.
Expanded Detail
EXPANDED:
The ADDRESS-LC trial has now completed its treatment phase, marking a key milestone for the investigational drug bezisterim. This study specifically targets the persistent cognitive impairment and fatigue often reported by individuals with long COVID
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
GSK advances mRNA flu shot to late-stage trial after positive Phase 2 data · Infectious disease
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Phase 2 Trial of Bezisterim for Neurological Symptoms of Long COVID: Treatment Phase Completed.” Browse more stories.